| Whole-cell segmentation of tissue images with human-level performance using large-scale data annotation and deep learning NF Greenwald, G Miller, E Moen, A Kong, A Kagel, T Dougherty, ... Nature biotechnology 40 (4), 555-565, 2022 | 412 | 2022 |
| Evolutionary conservation of microRNA regulatory circuits: an examination of microRNA gene complexity and conserved microRNA-target interactions through metazoan phylogeny CT Lee, T Risom, WM Strauss DNA and cell biology 26 (4), 209-218, 2007 | 302 | 2007 |
| Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models J Lin, D Sampath, MA Nannini, BB Lee, M Degtyarev, J Oeh, H Savage, ... Clinical Cancer Research 19 (7), 1760-1772, 2013 | 283 | 2013 |
| MIBI-TOF: A multiplexed imaging platform relates cellular phenotypes and tissue structure L Keren, M Bosse, S Thompson, T Risom, K Vijayaragavan, E McCaffrey, ... Science advances 5 (10), eaax5851, 2019 | 271 | 2019 |
| Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma T Risom, DR Glass, I Averbukh, CC Liu, A Baranski, A Kagel, ... Cell 185 (2), 299-310. e18, 2022 | 196 | 2022 |
| Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer T Risom, EM Langer, MP Chapman, J Rantala, AJ Fields, C Boniface, ... Nature communications 9 (1), 1-17, 2018 | 157 | 2018 |
| MicroRNAs in mammalian development CT Lee, T Risom, WM Strauss Birth Defects Research Part C: Embryo Today: Reviews 78 (2), 129-139, 2006 | 95 | 2006 |
| Activation of PP2A and inhibition of mTOR synergistically reduce MYC signaling and decrease tumor growth in pancreatic ductal adenocarcinoma BL Allen-Petersen, T Risom, Z Feng, Z Wang, ZP Jenny, MC Thoma, ... Cancer research 79 (1), 209-219, 2019 | 73 | 2019 |
| Pyrazolopyridine inhibitors of B-RafV600E. Part 2: Structure–activity relationships S Wenglowsky, KA Ahrendt, AJ Buckmelter, B Feng, SL Gloor, S Gradl, ... Bioorganic & medicinal chemistry letters 21 (18), 5533-5537, 2011 | 68 | 2011 |
| Pyrazolopyridine Inhibitors of B-RafV600E. Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors S Wenglowsky, L Ren, KA Ahrendt, ER Laird, I Aliagas, B Alicke, ... ACS Medicinal Chemistry Letters 2 (5), 342-347, 2011 | 67 | 2011 |
| Discovery of pyrrolopyrimidine inhibitors of Akt JF Blake, NC Kallan, D Xiao, R Xu, JR Bencsik, NJ Skelton, KL Spencer, ... Bioorganic & medicinal chemistry letters 20 (19), 5607-5612, 2010 | 65 | 2010 |
| Discovery and SAR of spirochromane Akt inhibitors NC Kallan, KL Spencer, JF Blake, R Xu, J Heizer, JR Bencsik, IS Mitchell, ... Bioorganic & medicinal chemistry letters 21 (8), 2410-2414, 2011 | 46 | 2011 |
| Deregulating MYC in a model of HER2+ breast cancer mimics human intertumoral heterogeneity T Risom, X Wang, J Liang, X Zhang, C Pelz, LG Campbell, J Eng, K Chin, ... The Journal of clinical investigation 130 (1), 231-246, 2020 | 39 | 2020 |
| Discovery of dihydrothieno-and dihydrofuropyrimidines as potent pan Akt inhibitors JR Bencsik, D Xiao, JF Blake, NC Kallan, IS Mitchell, KL Spencer, R Xu, ... Bioorganic & medicinal chemistry letters 20 (23), 7037-7041, 2010 | 37 | 2010 |
| Pyrazolopyridine inhibitors of B-RafV600E. Part 4: Rational design and kinase selectivity profile of cell potent type II inhibitors S Wenglowsky, D Moreno, ER Laird, SL Gloor, L Ren, T Risom, J Rudolph, ... Bioorganic & medicinal chemistry letters 22 (19), 6237-6241, 2012 | 33 | 2012 |
| Multiplexed imaging analysis of the tumor-immune microenvironment reveals predictors of outcome in triple-negative breast cancer A Patwa, R Yamashita, J Long, T Risom, M Angelo, L Keren, DL Rubin Communications Biology 4 (1), 852, 2021 | 31 | 2021 |
| Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts SH Strand, B Rivero-Gutiérrez, KE Houlahan, JA Seoane, LM King, ... Cancer cell 40 (12), 1521-1536. e7, 2022 | 24 | 2022 |
| Modeling differentiation-state transitions linked to therapeutic escape in triple-negative breast cancer MP Chapman, T Risom, AJ Aswani, EM Langer, RC Sears, CJ Tomlin PLoS computational biology 15 (3), e1006840, 2019 | 23 | 2019 |
| The discovery of potent and selective pyridopyrimidin-7-one based inhibitors of B-RafV600E kinase L Ren, KA Ahrendt, J Grina, ER Laird, AJ Buckmelter, JD Hansen, ... Bioorganic & medicinal chemistry letters 22 (10), 3387-3391, 2012 | 23 | 2012 |
| Multiplexed ion beam imaging: insights into pathobiology CC Liu, EF McCaffrey, NF Greenwald, E Soon, T Risom, K Vijayaragavan, ... Annual Review of Pathology: Mechanisms of Disease 17, 403-423, 2022 | 20 | 2022 |
